Tango trial shows 82 percent response in pancreatic cancer combo therapy

Clinical trial results reported Friday indicate that a combination of an experimental drug from Tango Therapeutics and Revolution Medicines’ Rasonque achieved tumor responses in 82% of patients with a specific type of advanced pancreatic cancer. The study also found that the responses were durable, with 88% of patients remaining alive without tumor progression at the nine-month assessment point. These figures support the hypothesis that targeted drug combinations may offer greater benefits to pancreatic cancer patients than single-agent treatments. The regimen is distinct for its exclusion of chemotherapy, which has traditionally been a standard treatment for this aggressive disease.